Vedolizumab as first-line biological therapy in elderly patients and those with contraindications for anti-TNF therapy: a real-world, nationwide cohort of patients with inflammatory bowel diseases

Mohamed Attauabi, Camilla Höglund, Janne Fassov, Kenneth Bo Pedersen, Heidi Bansholm Hansen, Signe Wildt, Michael Dam Jensen, Anders Neumann, Cecilie Lind, Henrik Albaek Jacobsen, Ana-Maria Popa, Jens Kjeldsen, Natalia Pedersen, Akbar Molazahi, Kent Haderslev, Claus Aalykke, Torben Knudsen, Wojciech Cebula, Pia Munkholm, Flemming BendtsenJakob Benedict Seidelin, Johan Burisch

Research output: Contribution to journalJournal articleResearchpeer-review

Fingerprint

Dive into the research topics of 'Vedolizumab as first-line biological therapy in elderly patients and those with contraindications for anti-TNF therapy: a real-world, nationwide cohort of patients with inflammatory bowel diseases'. Together they form a unique fingerprint.

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science